Invest in NasaClip

ER doctor & mom designed solution to nosebleeds: a $5B market

$2,611,586

of a $3,060,000 goal
INVESTMENT TERMS
Priced Round
$12M pre-money valuation
$250, $5K, $25K

Highlights

VC-Backed

Raised $250K or more from a venture firm

1
Customers: Disney, Doctors on Duty, Adventist Healthcare & University of Maryland Medical System
2
Backed by VCs: Blue Cross Blue Shield MA, Conscious Venture Partners, Portfolia, The Impact Seat
3
Awarded National Science Foundation Innovation Research Phase I grant funding ($256K value)
4
5 patents granted & 2 pending; FDA-registered, Class I 510(k)-exempt device

Featured Investors


Our Team


Pitch

NasaClip is the "Band-Aid" for nosebleeds, driving innovation in a $5B market with a doctor-designed, hands-free solution to an incredibly disruptive and common problem—affecting 60% of the population and leading to over 500,000 ER visits each year.

Designed and led by ER physician Dr. Elizabeth Clayborne along with experts and top executives from Duke, Dartmouth, Oatly, and Johnson & Johnson, our early traction shows growing demand for a fast, safe, and easy treatment for nosebleeds in both medical and consumer sectors.

Backed by notable investors including Blue Cross Blue Shield Massachusetts, TEDCO, Conscious Venture Partners, Portfolia, Women of Color in Pharma, and The Impact Seat, as well as funding from the National Science Foundation, NasaClip is on track to becoming a must-have in hospitals, homes, and first aid kits everywhere, reducing the stress of nosebleeds and improving quality of life for millions.



Nosebleeds are extremely common, yet stressful and often mismanaged. 

Nosebleeds can happen at any time - at school, during dinner, aboard a plane, while playing sports, or at work. Children aged 2-10 and older adults 55-80 on blood thinner medications are particularly susceptible.

Most people don’t know how to properly treat a nosebleed and they turn to ineffective fixes such as tissues, gauze, or pinching the nose in the wrong place. 

These methods rarely work and can lead to more mess and aggravation, eventually ending with a time-consuming and costly trip to the ER.

Once at the ER, healthcare professionals lack a quick and easy way to treat nosebleeds, further compounding the stress and chaos caused by this simple injury.  

Effective nosebleed care is often out of reach where it's needed most, and many people live in fear of not being able to stop the bleeding quickly and discreetly. 

An easily treatable issue can quickly become a debilitating problem, disrupting daily life and causing unnecessary anxiety.

Introducing NasaClip. 

We’re pioneering the $5B nosebleed care market with a hands-free, fast-acting device that anyone can use, wherever they are.

Unlike rough tissues and bulky gauze, NasaClip combines comfortable, perfectly placed pressure with sponges that can deliver medications to stop bleeding quickly and cleanly. No stress, no mess—just fast relief.

NasaClip goes beyond convenience—it's a proven, ER doctor-designed device that brings medical-grade care for all ages to everyday situations, for everyone involved.

Whether at home, in the ER, or on the go, NasaClip provides quick and effective relief, taking the guesswork out of stopping nosebleeds.

NasaClip’s multi-patented, unique design and widespread applicability position us to capture a significant share of this massive market.

On the medical side, our serviceable market includes 400,000 public and private hospital sites, long term care centers, schools, and sports stadiums. On the consumer side, our serviceable market includes 190,000 pharmacies and convenience stores, in addition to direct-to-consumer sales to millions of Americans via Amazon and our Shopify-powered ecommerce store. 

With over $100K in revenue, 300 locations, and a $1.7M sales pipeline within months of our soft launch, we’re gaining traction in medical and B2B accounts. 

Target B2B accounts and examples of organizations who could benefit from our fast and effective nosebleed care include Mount Sinai, Atrium Health, JetBlue, Delta, and the Miami Dolphins, in addition to wholesale to pharmacy chains and other retail outlets. 

By the end of 2024, we will expand our reach on leading ecommerce platforms like Amazon and Shopify, as well as a retail launch anticipated in 2025.

NasaClip is led by Dr. Elizabeth Clayborne, a practicing ER physician with firsthand experience treating countless nosebleeds and 20K+ patients during her 10+ year tenure, as well as Romil Patel, a seasoned B2B and consumer go-to-market expert. Together, with a team of experts from Johnson & Johnson, Cardinal Health, and Oatly, we’ve built NasaClip into a market-ready solution with both medical validation and consumer appeal.

Sales are driven by single use, reusable kits, and refill packs. With margins averaging 75% and recurring revenue from restocking, we’ve established a strong foundation for long-term growth and profitability.

NasaClip’s device has clinical applications beyond nosebleed care. We’ve received National Science Foundation (NSF) Small Business Innovation Research Programs (SBIR) Phase I grant funding, and we are pursuing additional funding from the National Institute of Health to research the development of a novel intranasal drug delivery platform leveraging our device. 

Early indicators of success mean we are now pursuing the next stage of SBIR funding to further develop this platform for use with drugs such as Naloxone, benzodiazepines, analgesic medication, and migraine medication - serving an even broader $43B market.

We believe NasaClip offers significant exit potential across multiple sectors. As a first-of-its-kind, physician-designed device for nosebleed management, it is an attractive acquisition target for consumer device manufacturers, medical distributors, drug delivery companies, and retail chains. 

Strategic partners in healthcare, retail, or MedTech could leverage our strong IP portfolio and growing market presence to expand their product lines, enhance their offerings, and capture a share of this market which lacks effective and convenient solutions.

NasaClip is a no-brainer for millions of hospitals, schools, and homes. 

Venture investors including The Blue Cross Blue Shield of Massachusetts, Portfolia, and Conscious Venture Partners have invested and now, we’re inviting our patients, day-one supporters, future users, and community to invest on the same terms so we can bring NasaClip to the mass market.

Just as Band-Aid is the go-to brand for wound care, NasaClip is poised to become the trusted name for nosebleed management in every hospital, first aid kit, and medicine cabinet worldwide. Join us in building the doctor’s choice for nosebleed care—an iconic brand loved by caregivers and parents everywhere.

Invest in NasaClip today.


Overview